skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.09d (Release date: 2017-09-25)
SearchBox Top
SearchBox Bottom
Cetuximab (Code C1723)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Cetuximab

Definition: A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.

NCI-GLOSS Definition: A monoclonal antibody used to treat certain types of head and neck cancer, and colorectal cancer that has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Erbitux binds to the epidermal growth factor receptor (EGFR), which is found on the surface of some types of cancer cells.

Display Name: Cetuximab

Label: Cetuximab

NCI Thesaurus Code: C1723 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0995188  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Cetuximab
cetuximab
CETUXIMAB
Chimeric Anti-EGFR Monoclonal Antibody
Chimeric MoAb C225
Chimeric Monoclonal Antibody C225
Erbitux
IMC-C225

External Source Codes: 
CAS Registry Number 205923-56-4 (see NLM ChemIDplus info)
FDA UNII Code PQX0D8J21J
NSC Code 714692 (see NCI DTP info)
PDQ Closed Trial Search ID 42384
PDQ Open Trial Search ID 42384 (check for NCI PDQ open clinical trial info)
UMLS CUI C0995188

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Advanced colorectal cancer; Head and neck cancer
code C1723
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Cetuximab
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1723

Mainbox Bottom